Archived Announcements

Pre-Pregnancy vs. TDM Testing for Leflunomide & Teriflunomide

02/22/2014

Leflunomide (Arava®) and Teriflunomide (Aubagio®) are teratogenic drugs. This means that they are capable of harming an embryo or fetus. Toxicology testing is performed either for therapeutic drug monitoring to ensure adequate dosage OR to show teriflunomide (active metabolite of leflunomide) has been sufficiently eliminated prior to pregnancy.

The Pre-Pregnancy Monitoring tests have a reporting limit of 5 ng/mL. They are designed for measuring teriflunomide at low levels. These tests can be used to monitor the elimination of teriflunomide in patients who discontinue leflunomide or teriflunomide where it must be ensured that levels have sufficiently decreased, such as in women of childbearing potential.

2532 Leflunomide as Metabolite (Pre-Pregnancy Monitoring)
4367 Teriflunomide (Pre-Pregnancy Monitoring)

The Therapeutic Drug Monitoring tests have a reporting limit of 500 ng/mL. They are designed to monitor teriflunomide levels to ensure adequate dosage.

2531 Leflunomide as Metabolite (Therapeutic Drug Monitoring)
4366 Teriflunomide (Therapeutic Drug Monitoring)

« Return to News Listing